Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease

被引:140
|
作者
Nojgaard, C
Johansen, JS
Christensen, E
Skovgaard, LT
Price, PA
Becker, U
机构
[1] Univ Copenhagen, Hvidovre Hosp, Dept Gastroenterol, DK-2650 Hvidovre, Denmark
[2] Univ Copenhagen, Hvidovre Hosp, Alcohol Unit, DK-2650 Hvidovre, Denmark
[3] Univ Copenhagen, Hvidovre Hosp, Dept Clin Physiol & Nucl Med, DK-2650 Hvidovre, Denmark
[4] Univ Copenhagen, Hvidovre Hosp, Dept Rheumatol, DK-2650 Hvidovre, Denmark
[5] Bispebjerg Hosp, Clin Internal Med 1, DK-2400 Copenhagen, Denmark
[6] Univ Copenhagen, Dept Biostat, Copenhagen, Denmark
[7] Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA
关键词
YKL-40; human cartilage glycoprotein; PHINP; N-terminal propeptide of type III procollagen; alcoholic liver disease; liver fibrosis; prognostic marker;
D O I
10.1016/S0168-8278(03)00184-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: YKL-40 (growth factor) and PIIINP (N-terminal propeptide of Type III procollagen) are potential markers of liver fibrosis. The aim was to evaluate the prognostic value of serum YKL-40 and PIIINP levels in patients with alcoholic liver disease. Methods: Three hundred and seventy patients with alcoholic liver disease were studied in a trial of malotilate with a median follow-up period of 470 days; 75 patients died; 336 patients had a liver biopsy on entry. Serum levels of YKL-40 and PIIINP were determined by radioimmunoassay (RIA). Results: Serum YKL-40 and PIIINP were elevated in the patients compared to controls. Patients with steatosis or no fibrosis had the lowest serum levels of YKL-40 and PIIINP, whereas patients with alcoholic hepatitis and/or cirrhosis had the highest levels. Serum YKL-40 was associated with the presence of fibrosis, and serum PIIINP was also associated with the different grades of fibrosis. Patients with elevated serum YKL-40 or PIIINP had shorter survival than patients with normal serum levels of YKL-40 (P < 0.0001) or PIIINP (P = 0.044). High degree of fibrosis predicted shorter survival (P = 0.004). Conclusions: Serum levels of YKL-40 and PIIINP are elevated in alcoholic patients, related to the presence of liver fibrosis and may provide prognostic information. (C) 2003 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:179 / 186
页数:8
相关论文
共 50 条
  • [1] Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease
    Nojgaard, C
    Johansen, JS
    Christensen, E
    Skovgaard, LT
    Price, PA
    Becker, U
    [J]. JOURNAL OF HEPATOLOGY, 2003, 38 : 198 - 198
  • [2] Serum YKL-40 and PIIINP levels as prognostic markers in patients with alcoholic liver diseases.
    Noejgaard, C
    Becker, U
    Johansen, J
    Christensen, E
    Price, PA
    Skovgaard, LT
    [J]. HEPATOLOGY, 2002, 36 (04) : 399A - 399A
  • [3] Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease
    Erina Kumagai
    Yohei Mano
    Sachiyo Yoshio
    Hirotaka Shoji
    Masaya Sugiyama
    Masaaki Korenaga
    Tsuyoshi Ishida
    Taeang Arai
    Norio Itokawa
    Masanori Atsukawa
    Hideyuki Hyogo
    Kazuaki Chayama
    Tomohiko Ohashi
    Kiyoaki Ito
    Masashi Yoneda
    Takumi Kawaguchi
    Takuji Torimura
    Yuichi Nozaki
    Sumio Watanabe
    Masashi Mizokami
    Tatsuya Kanto
    [J]. Scientific Reports, 6
  • [4] Serum YKL-40 levels as a prognostic factor in patients with intracerebral hemorrhage
    Jiang, Yi-Xiang
    Zhang, Gui-Hong
    Wang, Zhi-Min
    Yang, Hui
    [J]. CLINICAL BIOCHEMISTRY, 2014, 47 (18) : 302 - 306
  • [5] Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease
    Kumagai, Erina
    Mano, Yohei
    Yoshio, Sachiyo
    Shoji, Hirotaka
    Sugiyama, Masaya
    Korenaga, Masaaki
    Ishida, Tsuyoshi
    Arai, Taeang
    Itokawa, Norio
    Atsukawa, Masanori
    Hyogo, Hideyuki
    Chayama, Kazuaki
    Ohashi, Tomohiko
    Ito, Kiyoaki
    Yoneda, Masashi
    Kawaguchi, Takumi
    Torimura, Takuji
    Nozaki, Yuichi
    Watanabe, Sumio
    Mizokami, Masashi
    Kanto, Tatsuya
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [6] Serum YKL-40 levels in patients with coronary artery disease
    Kucur, Mine
    Isman, Ferruh K.
    Karadag, Bilgehan
    Vural, Vural A.
    Tavsanoglu, Sedat
    [J]. CORONARY ARTERY DISEASE, 2007, 18 (05) : 391 - 396
  • [7] Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease
    Tran, A
    Benzaken, S
    Saint-Paul, MC
    Guzman-Granier, E
    Hastier, P
    Pradier, C
    Barjoan, EM
    Demuth, N
    Longo, F
    Rampal, P
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2000, 12 (09) : 989 - 993
  • [8] Elevated serum YKL-40 levels in patients with Kawasaki disease
    Kim, K. Y.
    Ahn, Y.
    Kim, D. Y.
    Kim, Ho-Seong
    Kim, D. S.
    [J]. BIOMARKERS, 2017, 22 (3-4) : 326 - 330
  • [9] Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease.
    Tran, A
    Benzaken, S
    Marine-Barjoan, E
    Hastier, P
    Saint-Paul, MC
    Christian, P
    Demuth, N
    Rampal, P
    [J]. HEPATOLOGY, 2000, 32 (04) : 191A - 191A
  • [10] Increased serum levels of YKL-40 in patients with inflammatory bowel disease
    Ioannis E. Koutroubakis
    Efthymia Petinaki
    Philippos Dimoulios
    Emmanouel Vardas
    Maria Roussomoustakaki
    Antonios N. Maniatis
    Elias A. Kouroumalis
    [J]. International Journal of Colorectal Disease, 2003, 18 : 254 - 259